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Fluoroquinolones II 
Decreasing susceptibility of Neisseria 
gonorrhoeae to fluoroquinolones in Greece 
A. Mavroidi', H. Avgerinou*, M. Gazouli', H. Dimopoulou', E. 
Fragouli2, E. Tzelepi'. 'Department of Bacteriology, Hellenic Pasteur 
Institute, ZMicrobiology Department, 'Andreas Sygros' S T D  Hospital, 
Athens, Greece 
Objectives: To investigate strain-clonality as the possible cause for 
decreasing susceptibility to fluoroquinolones in populations of gono- 
cocci isolated in Greece after 1990. 
Methods: A total of 520 N gonorrhoeae strains isolated consecu- 
tively during the years 1990-97 were characterized by conventional 
typing and antibiotic susceptibility determination using Etest. Strains 
with ciprofloxacin MICs 0.006 mg/L were further analyzed by 
pulsed-field gel electrophoresis (PFGE) after digestion of genomic 
DNA with Spel endonuclease. 
Results: Ciprofloxacin MICW for gonococci isolated yearly 
increased progressively from 0.006 in 1990 to 0.125 mg/L through 
1997. The 70% of the isolates with ciprofloxacin MICs 0.006 mg/L 
constituted two clusters with character combinations not encoun- 
tered among strains more susceptible to fluoroquinolones. One clus- 
ter consisted of multiresistant strains with B[r]opyst Ph-serovars that 
exhibited ciprofloxacin MICs of 0.008-0.023 mg/L; such strains 
appeared in Greece in 1991 and their frequency increased from 5% 
to 32% through 1997. The second cluster comprised strains belong- 
ing to a single Ph/GS-serovar/auxotype/plasmid-content combina- 
tion (Arst/IA-6/NR/conjugative + cryptic), exhibiting ciprofloxacin 
MICs of 0.047-0.125 mg/L and being fully susceptible to all other 
antibiotic classes. These strains emerged in 1996 and accounted for 
5.5% and 10.8% ofgonococci isolated in 1996 and 1997, respectively. 
By PFGE typing, B[r]opyst strains divided into two closely related 
types, with two subtypes each; those of the Arst/IA-6 cluster were 
identical, constituting a third, distinct type. 
Conclusions: Decreasing susceptibility to fluoroquinolones in 
our N. gonorrhoeae samples was mainly due to clonal spread of a few 
strain types. 
[p7881 Experimental fluoroquinolone resistance of 
Vibrio cholerae eltor 
I.V. Ryzhko, R.I. Tsurajeva, Yu. M. Lomov, B.N. Mishankin. 
Laboratoryfor Featment o j  Irlfectious Diseases, Institutefor Plague 
Control, Rostov-on-Don, Russia 
Objectives: To investigate the possibility of experimentally obtain- 
ing fluoroquinolone-resistant (Fqn') strains of K cholerae with partic- 
ular emphasis on the perspectives of antibiotic treatment of cholera 
caused by such strains. 
Methods: In our experiments the strain Mbrio cholerae eltor P-5879 
susceptible to antimicrobial agents was used. We obtained the Fqn'- 
mutants by a method of multiple subcultivation of K cholera on the 
solid nutritious medium with increasing concentrations of cipro- 
floxacin, ofloxacin, pefloxacin and norfloxacin. Susceptibility testing 
was done using Mueller-Hinton agar. Therapeutic efficiency of the 
drugs was evaluated on a model of cholera septicemia in white mice, 
challenged intraperitoneally with an inoculum of 10' V cholera cells. 
Results: The susceptibility of the initial P-5879 strain to tetracy- 
clines, trimethoprim/sulfamethoxazole, aminoglycosides, quino- 
lones, B-lactams, rifampicin and furazolidone corresponded to their 
efficiency in vivo (SO-lOO% of the animals survived). The Fqn' 
mutants were resistant to all fluoroquinolones (MICs=3.2-12.8 
mg/L) and nalidixic acid (MICs=400-800 mg/L). It was possible to 
select from the population of Fqn' mutants clones with an initial level 
of virulence for rabbit sucklings. Fqn' mutants caused an infectious 
process in mice which &d not recover after quinolones, ampicillin 
and cephoperason; the efficiency of rifampicin, cefotaxime and 
ceftriaxone was considerably reduced (2G30% of the mice survived). 
The theurapeutic activity was restricted to tetracyclines, aminogly- 
cosides, trimethoprim/sulfamethoxazole and furazolidone. 
Conclusions: The danger of involvement of Fqn' mutants of V 
cholera in the epidemic process requires usage of fluoroquinolones for 
treatment of this infection only in prescribed dosages and recom- 
mended routes of administration with simultaneous laboratory 
control for efficiency of antibacterial treatment. 
I P789 I Multicenter in vitro comparison of levofloxacin 
with other antibiotics against hospital isolates 
R. Frei for the Swiss in Vitro Study Group. Bacteriology Laboratory, 
University Clinics, Basel, Switzerland 
Objectives: To evaluate the current susceptibility of clinically signif- 
icant bacteria from hospitalized patients to levofloxacin (LEV) in 
comparison with commonly used anti-infectives, such as ofloxacin 
(OFL), ciprofloxacin (CIP), ceftazidime (CAZ), amoxycillin/clavu- 
lanic acid (A/C), imipenem (IMI) and clarithromycin (CLA). 
Methods: MICs were determined in 9 medical centers by using 
the Etest. 
Results: A total of 2169 isolates were tested. MIC~OS ( mg/L) were 
as follows: 
M.&arrha/is(44) I 0.125 I 0.25 1 0.125 I 0.5 1 0.25 I 0.06 I 0.25 
H. influenme (125) I 0.03 I 0.06 I 0.03 I 0.25 I 1 I 8 I 32 
Conclusions: Levofloxacin was at least two-fold more potent 
than ofloxacin for most isolates. It demonstrated broad-spectrum 
activity against the commonly isolated pathogens of respiratory tract 
infections. 
[q Characterization of mutant fluoroquinolone- 
resistant Streptococcus pneumoniae selected 
with ciprofloxacin or moxifloxacin 
H. Kent, V Ricci, L.J.V. Piddock. Antimicrobial Agents Research 
Group, Division o f  Immumlogy and Infertion, University of Birmingham, 
Birmingham, UK 
The ability of ciprofloxacin (CIP) compared with moxifloxacin 
(MOX; Bay 12-8039) to select mutant Streptococcus pneumoniae (M3 
capsulated, M4 no capsule) on agar with decreased susceptibility was 
compared. First step (Fl) mutant S. pneumoniae with decreased fluo- 
roquinolone (FQ) susceptibility could be selected with CIP, but not 
MOX. Mutant strains (F2) with further decreases in susceptibility 
were selected from a parC mutant with both CIP and MOX at 
frequencies of mutation suggestive of mutation in a single gene. The 
F1 mutants of M3 either contained a mutation substituting Ser79 for 
Ala in ParC, or. had a phenotype suggestive of an efflux mutant. No 
mutations in the Q R D R  of XyA, gyrB or parE were detected. F1 
mutants with several phenotypes were obtained from M4; none had 
A b s t r a c t s  
Conclusions: Combination of trovafloxacin with clindaniycin or 
mctronidazole niay be useful when trovafloxacin MICs cluster around 
the susceptible breakpoint of <: = 2  pg/inL. 
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Non sporulated rods (43) 0.5/2 1 /4 118 
Peptostreptococcus (43) 0.125/0.5 1/16 I18 
All gram + ( 136) 0.25/1 118 0.5/8 
All anaerobes (358) 0.25/2 2/8 4/16 
3 mutation in the Q R D K  ofparC, ZyrA, ,gvB or parE, and all had an 
efflux mutant phenotype, but with differing susceptibilities to antibi- 
otics, suggestive of varying e.rpression of an efflux pump. All F2 
mutants selected with CIP or R4OX had no further niutation inparC, 
or any mutation in the QRDR of the other three genes. All F2 
mutants were highly resistant to CIP (MIC 64 pg/mL) and less 
susceptible to new FQs (MICq 0.5-16 pg/mL). 
Anti-anaerobic synergy of trovafloxacin with 
clindamycin or metronidazole by checkerboard 
and time-kill 
L. Ednie, K. Credito, M.R. Jacobs, PC. Appelbaum. Departmen, qf 
Pai/ioiofi, Hersfzcy Medical C ~ ~ t e r ,  Hurshcy, PA; Case Wstern Reserve 
Uriiverxity, C l e ~ e l n ~ i d ,  OH, USA 
Objectives: To test the anti-anaerobic activity of trovafloxacinkclin- 
damycin and metronldazole. 
Methods: For 113 strains, checkerboard titration was used. Four 
strains were tested by time-kill methodology. 
Results: MICjl,/,,os (~.~g/niI,) of drugs alone were: 
Drug B.fraa gp (45) Prev/Porph (20) Fuso (8) PeDtostr (18) 
Trova 0.25/0.5 1.0/2.0 0.51. 0.125/0.5 0.25/0.5 
Clinda 0.5/2.0 0.008/0.016 1.01. 0.25/0.5 1.0/2.0 
Metro 1.0/2.0 2.0/2.0 O X / .  1.0/2.0 1.014.0 
In checkerboard tests, 2 B. -fiqilir group showed synergistlc FICs 
(< =0.5) with trovafloxacin tclindamycin and 5 with trova- 
floxacin+nietronidazole. One F~rsobacterium showed synergy with 
trovafloxacin+metronidazole. Other FIC indices were additive/ 
indifferent (0.5-4) and no antagonistic FlCs (4) were found. For 4 
anaerobes (additive FICs) tested by time-kill, synergy (= 100 
CFU/niL drop at 48 h comparrd to the more active drug alone) was 
found for 1 B. j q i l i s ,  1 B. theta and 1 E uariurn at sub-MIC 
trovafloxacin concentration 0.12551 pg/niL in combination with 
concentration < = the MICs ofclindamycin and metronidazole. One 
I! hivia did not show synergy between trovafloxacin and clindamycin, 
but synergy between trovafloxacin (at the MIC) and metronidazole 
(1 dilution below MIC) was found. 
(22) 
M I C m  with all three methods were 2.0 and 8.0-1 6.0 pg/mL, respec- 
tively. The numbers of strains S, I and K by disk were 74, 4 and 23, 
compared to 71, 7 and 23 with agar dilution, 72, 13 and 16 with 
microdilution and 61, 24 and 26 with Etest. All pneuniococci were 
S with all four methods, with MICicls and MICu1,s of ~1.0641.125 
pg/inL and (1.125-0.25 pg/niL. By disk, 3 major and 0 very major 
errors occurred with I? aeq inosa .  Corresponding numbers with 
MRSA were 1 and 1 .  No errors occurred with S. pneumoniac. When 
microdilution and Etest MICs were compared with agar dilution, 
91-101 strains in each species gave essential agreerncnt. Two P aen4,q- 
irrosa gave very major errors with microdilution. 
Conclusions: Disk, agar and microdilution can be used for 
trovafloxacin testing of I! nerucqinosa and MRSA; Etest MICs are 
higher than those with agar and microdilution; all four method\ can 
be recommended for pneumococci. 
Antianaerobic activity of trovafloxacin 
compared with those of ofloxacin, 
ciprofloxacin, imipenem and metronidazole 
L. Dubreuil’, E. Singer’, A. Sedallian’, S. Bland2. ‘Depantmcnr I$ 
M i c r o b i o / u ~ ,  Faculty i$ Pharmacy, Lille, ’Annecy Huspital, Anwry, 
France 
Objectives: MICs were determined for trovafloxacin (TKO), 
ofloxacin (OFL), ciprofloxacin (CIP), iinipeneni (IMI) and metron- 
idazole (MOL) against 358 anaerobes isolated from human clinical 
samples. 
Methods: Reference agar dilution (standard M11 A4, NCCLS). 
Results: TRO, OFL and CIP inhibited at 4 mg/L respectively 
96%, 62% and 38% of the B..fiqilis group strains, whereas resistance 
rates were respectively MOL 0’%, IMI 4%. Considering the three 
fluoroquinolones, the MICw,/slis (nig/L) were: 
Other gram negative (82) 0.2514 118 0.25/4 
C. perfringens (12) 0.125/0.125 0.510.5 0.25/0.25 
C. difficile (27) 0.5/1 4/8 8/8 
Comparison of four methods to test 
trovafloxacin activity against /? aeruqinosa, S. 
aureus and pneumococci 
L.M. Kelly, M.R. Jacobs, PC. Appelbaum. Department of Pathology, 
Hershey M d i c a l  Cewer, Hwhey, PA; Case Western Reseruc University, 
Cleveland, OH,  USA 
Objectives: To compare four in vitro methods for laboratory test- 
ing of trovafloxacin against 303 organisms belonging to three groups. 
Methods: Agar and microdilution MICs in air (NCCLS), and 
Etest and disk diffusion in air (COz, for pneumococci) (XNCCLS) 
tested activity of trovafloxacin against 101 I? aevtcqinora, 101 methi- 
cillin-R S. aweus (MRSA), and 101 pneuniococci. MIC breakpoints 
(pg/mL) (S, I, R) were <=2, 4 and =8 for F? acvtcqinosa and MKSA, 
and < = 1 ,  2 and = 4  for pneumococci. Corresponding diffusion 
zones (mm) were =17, 14-16, <=13, and =19, 16-18, and <=15.  
Results: For l? arnrqinosa, MICslIs and M I C m  with all three 
methods were 1.0-2.0 pg/mL and 8.0-16.0 pg/mL. The numbers of 
I! aemqima S, I and R by disk diffusion were 60, 11 and 30, 
compared to 65, 15 and 21 with agar dilution, 7 3 , l l  and 37 with 
microdilution and 59, 20 and 22 with Etest. For MRSA, MICsl,s and 
TRO, unlike other fluoroquinolories, demonstrated high activity 
against the B , j a &  group and clostridla. TRO was also iiiore potent 
than OFL and CIP against Gram-positive rods and anaerobic cocci. 
O f  358 anaerobes, TKO inhibited 87%, 92% and 99% of the strains 
investigated at concentrations of 1 ,  2 and 4 nig/L, respectively. 
Conclusions: The broad anaerobic spectrum of T R O  demon- 
strated in vitro is promising for the treatnient of intra-abdominal 
infections: further clinical evaluation is needed. 
I P794 I Anaerobes and trovafloxacin: influence of pH, 
inoculum, type of media, killing effect and 
activity in combination with vancomycin, 
ceftazidime and metronidazole 
L. Dubreuil, E. Singer. Departrnenf ofM~crobiol~,~g, F a d f y  qf 
Pharmacy, Liflc, France 
Objectives: MICs were determined 011 trovafloxacin (TRO), using 
Brucella or Wilkins Chalgren, at three pH values (5.6, 6.8, 7.1) and 
three different inocula against 27 anaerobes. Killing effect and coinbi- 
nations were determined on 5 strains of the B..fiaxific Sroup. 
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Enterobacteriaceae(320) 93 93 91 91 
Non-femnters(185) 75 72 62 60 
Methods: Reference agar dilution (standard M 1 1 A4 NCCLS) 
for MICs, checkerboard technique for combinations, and killing 
curves for TRO alone. 
Results: The MICs of T R O  were nearly identical when tested at 
pH 7.1 on Brucella blood agar (BBA) or Wilkins Chalgren agar 
(WC) but were 2- and 4-fold higher at pH 5.8 on BBA or WC, 
respectively. Inoculum effect was low. TRO demonstrated a bacteri- 
cidal activity at 4 MIC (3 strains) or 8 MIC (2 strains). Against 5 B. 
fragilis group strains, the combinations of TRO with metronidazole 
were synergistic 1/5 or additive 4/5 (checkerboard technique); 
meanwhile, the MICs of TRO were unchanged in the presence of 4 
mg/L of ceftazidime (CAZ) but were 1-2-fold dilutions lower in the 
presence of 4 mg/L of vancomycin (VAN) or a triple combination 
with 4 mg/L of both VAN and CAZ (therapeutically achievable 
levels). 
Conclusions: TRO demonstrated a broad spectrum and killing 
effect against anaerobes. Combinations of TRO with drugs such as 
vancomycin and ceftazidime never alter the activity of T R O  against 
strains of B. fragilis and may offer some benefit. 
87 83 99 99 
32 87 77 90 
Comparative activities of six different 
fluoroquinolones against 9682 bacterial 
isolates from 20 European university hospitals 
E-J. Schmitz, J. Verhoef, A. Fluit. T h e  SENTRY Participants Group, 
Eijkman- Winkler Institute f o r  Medical Microbiology, Utrerht, The 
Netherlands 
Objectives: To compare the in vitro activities of gatifloxacin, trova- 
floxacin, levofloxacin, sparfloxacin, ofloxacin and ciprofloxacin 
against European isolates. 
Methods: Antimicrobial susceptibility testing of 9682 clinical 
bacterial isolates from 12 countries. The strains were collected during 
the first year of the SENTRY Antimicrobial Surveillance Program 
(April 1997 to April 1998). 
Results: Gatifloxacin and trovafloxacin exhibited the best activi- 
ties against Gram-positive cocci, while levofloxacin, ofloxacin, cipro- 
floxacin and gatifloxacin were the most active of the compounds 
tested against Enterobacteriaceae. Ciprofloxacin and levofloxacin 
showed the best antimicrobial activities against Pseudomonas spp., 
while gatifloxacin and trovafloxacin were the most active compounds 
tested against Acinetobacter spp. and Stenotrophomonas maltophilia. All 
Haemophilus spp. and Moraxella catarrhalis isolates were fully suscepti- 
ble to all quinolones tested. Although the proportion of susceptible 
and resistant strains within some species varied substantially between 
different university hospitals, the relative activities of the quinolones 
tested were the same in each institution. 
Conclusions: Overall, the new investigational quinolones tested, 
especially gatifloxacin, showed improved activity against Gram- 
positive cocci and Gram-negative non-fermenters while retaining 
broad-spectrum activity against Gram negative bacilli. Pre-existing 
ciprofloxacin resistance was associated with increased MIC values for 
the newer fluoroquinolones, indicating a reduced efficacy of these 
compounds against ciprofloxacin-resistant isolates. Geographic differ- 
ences in the prevalence of quinolone-resistant bacteria might be 
explained by extensive quinolone usage and/or horizontal clonal 
spread of resistant bacteria within the different European university 
hospitals. 
iP796 I In vitro comparative activity of trovafloxacin 
(Tv) tested against aerobic, anaerobic and 
penicillin (PCN)-resistant Streptococcus 
pneumoniae using the Etest 
A. Gupta, M. Saquib, G. Archer, V Chau. Department ofMedicine, 
hah(qh Valley Hospital, Allentown, PA, USA 
Objectives: To study the in vitro activity of the new fluorinated 
quinolone TV against common pathogens compared to levofloxacin 
(LE), ciprofloxacin (CI), ceftriaxone (TX), cefuroxime (XM), imi- 
penem (IP), cefoxitin (FX), metronidazole (MZ) and clindamycin 
(CM) using Etest. 
Methods: Standard materials and methods for Etest were followed 
using NCCLS quality control guidelines. Standard ATCC quality 
control strains were used. We tested activity against 238 Gram-posi- 
tive, 319 Gram-negative and 110 anaerobic organisms. We also 
included 30 PCN-sensitive (S) and 65 PCN-resistant (R) Streptococcus 
pneumoniae. 
Results: TV inhibited 95% or more of all aerobic and 94% or 
more of all anaerobic organisms. TV MICjo and MICYO were signif- 
icantly lower compared to the antibiotic tested. S. aureus: 
MICso=0.033, MICso=0.047. Coagulase-negative staphylococci: 
MICso=0.5, MICslp2.0. S. pneumoniae: MICr1=0.047, MICw= 
0.125. E. roli: MICso=0.032, MICvo=0.064. Pseudomouar aeruginosa: 
MICsr1=0.38, M I C W = O . ~ ~ .  PCN -R S. pneumoniae: MICi~=0.094, 
MIC~r1=0.125. B.fragi/ir: MIC~,=0.125, MICw=50. c. perfringens: 
Conclusions: Trovafloxacin, a new fluorinated quinolone deriv- 
ative, had expanded activity against common Gram-negative, Gram- 
positive and anaerobic pathogens including PCN-R S. pneumoniae. 
Overall, TV demonstrated lower MICjo and MICw values compared 
to antibiotics tested. 
MICwi=0.50, MICyo=l.O. 
In vitro activity of trovafloxacin against 
Enterobacteriaceae and non-fermenters from 
pediatric patients 
Abstracts 2 9 9  
Aerobes 
E. wli 3 8 4 4  4 6 0 9 
E.faecalis 109 10 37 21 3 0 
N I TRV] CIP I LEV I IMP I PUS 
lp7981 Activity of trovafloxacin alone and combined 
with other drugs against Enterobacteriaceae 
by MIC and time-kill 
CTM CRO GEN 
5 0 10 
100 100 97 
C.L. Clark, M.K. Jacobs, P.C Appelbauni. Patholo~y, Hershey 
Medical Center, Hershey, PA; C(ise Western Reserve University, 
Cleveland, O H ,  LISA 
Objectives: To test the activity of trovafloxacin, ciprofloxacin, 
levofloxacin, ceftazidime, cefotaxime, imipeneni and ampicillin/ 
sulbactani against 14 Enterobacteriaceae, and trovafloxacin+cefta- 
zidime and aInpicillin/sulbactaiii against 8 strains. 
Methods: Microdilution MIC and time-kill (synergy in combi- 
nation studies 100 CFU/mL drop conipared to more active drug) 
(MIC at 24 h). 
Results: MICs (pg/niL): trovafloxacin, 0.008-0.25; ciprofloxacin, 
0.008-0.12; Ievofloxacin, 0.O'Lh4.12; ceftazidime, 0.12-32; cefo- 
taxime, 0.034; iniipeneni, (1.124; anipicillin/sulbactani, 4-128. 
Numbers strains with -1, -2 and -3 loglf, decreases in count at MIC 
conipared to 0 h were ds follows: 
- 2 h 4 h  6 h  12h 2 4 h  
-1 -2 -3 -1  -2 -3 -1 -2 -3 -1 -2 -3 -1 -2 -3 
Trovafloxacin 1 2 1 0 6  1 3 8  5 1 4 1 3 7  8 7 2 8 3 1 
Ciprofloxacin 13 10 5 '13 12 8 13 11 7 4 2 2 6 3 2 
Levofloxacin 1 2 9  5 '128 5 1 2 9  7 5 4 2 4 2 2 
Ceftazidime 9 7 3 8 7 4 1 1 1 0 3  8 8 2 8 6 2 
Cefotaxime 8 4 1 1 2 7 4 1 2 7 4 7 4 3  5 3 3  
lmipenem 8 6 3 138 3 1 2 7  6 6 4 3 8 6 5 
Ampieillin/Sulbactam 10 7 1 11 9 3 9 8 5 6 5 4 6 5 4 
Synergy (24 h) occurred between trovafloxacinfcefiazidime and 
trovafloxacin+ atnpicillin/siilbactani in 4 strains and trovafloxacin + 
ceftazidime in 2 strains. Synergy (4-12 h) occurred for trova- 
floxacin+ceftazidime and trovafloxacin+ampicillin/tulbactani in 1, 
and trovafloxacin +ampicillin/sulbactani in 2 strains. 
Conclusions: Synergy occiirred with trovafloxacin+ ceftazidime 
and ampicillin/sulbactam at sub-MIC trovafloxacin concentrations, 
and regrowth often seen with trovafloxacin alone after 12-24 h was 
eliminated, with bactericidal activity in the combination. 
Anaerobes N TRV CIP LEV IMP PUS PEISI CLI YTR 
B.fragilis 423 2 73 29 0 2 6 9 0 
,B.thetaiota. 266 3 77 41 0 0 7 9 0 
[p7991 lntraphagocytic activity of trovafloxacin 
C. Wallrauch, D. Milatovic, V. Vatou, 1. Braveny. Institute of Medical 
M i m  bidoyy, Trill  w icai C iniuersity. Munich, Germariy 
Objectives: To examine the uptake of the new yuinolone trova- 
floxacin (trova) by human polymorphonuclear leukocytec (PMNLs), 
and study the capacity of trova to kill phagocytosed Staphylococcus 
atirciis. 
Methods: An overnight culture of S. aurees was washed and 
suspended at d concentration of 2 X 10' CFU. PMNLs were incu- 
bated with varying concentrations of trova. After sonication and 
centrifugation, the bactericidal activity of the sonicate was bioassayed 
by agar plate diffusion technique using E. coli as the test organism, S. 
atireus opsonized in 10% human pool serum was exposed to the 
PMNLc a t  37%. Extracellular bacteria were removed by adding 
lysostaphin. The PMNLs with ingested S. anreids were resuspended 
and various concentration5 of trovd were added. Then the suspension 
was incubated. The iiitracellular survival of S. aercus was deterniincd 
after 0, 3 and 18 h of Incubation with serial 10-fold dilutions of 100- 
pL samples. 
Results: The uptake of mova was rapid and the intracellular 
concentration 4-5 times higher than the extracellular concentration. 
Afcer 3 h of incubation, trova showed no effect a t  concentrations 
below the MIC, but at IOXMIC the iiitracellular rate o f S  aureus was 
reduced by half a log conipared to the phagocytic control assay. At 
the same time a marked bactericidal activity was noted at 1 XMlC 
and 10XMIC on extracellular S. aurees with a 3-4 log reduction of 
viable bacteria. After 18 h ofincubation, trova did reduce the number 
of viable intracellular S. aumus at 1 XMIC and IOXMIC, although 
the efiect was more pronounced on extracellular S. aiirriis. 
Conclusions: Trovafloxacin showed good intracellular activity 
against phagocytosed staphylococci and may be an option for the 
treatment of infections due to facultative intracellular organisins. 
JP800] In vitro activity of trovafloxacin and other 
broad-spectrum antimicrobial agents against 
peritonitis isolates 
J. Focht. Mikrobiolofie, Bioscieetia-Labor, Mocrs, Germany 
Objectives: To investigate the in vitro activity of trovafloxacin and 
other broad-spectrum antimicrobial agents against peritonitis isolates. 
Methods: Consecutive peritonitis isolates were tested for antibi- 
otic wsceptibility using microdilution methods (DIN 58940). Trova- 
floxacin (TRV), ciprofloxacin (CIP), levofloxactn (LEV), piperacillin/ 
sulbactani (PI/S) and imipenem (IMP) were tested againct both aero- 
bic and anaerobic pathogens. Cefotiam (CTM), ceftriaxone (CRO) 
and gentaniicin (GEN) were tested against aerobes only, and peni- 
cillin G/suIbactarn (PEIS), clindaniycin (CLI) and metronidazole 
(MTR) were tested against anaerobes only. 
Results: A total of 2124 isolates were investigated: 806 (38%) 
Grani-negative aerobes, 203 (10%) Gram-positive aerobes, and 11 15 
(52'?4) anaerobes. The tables show the percentage of resistant strains 
for the tiiost frequent species ( n  100) based on DIN 58940 break- 
points. 
Ip8011 In vitro activity of trovafloxacin, moxifloxacin 
and ciprofloxacin against Bordetella pertussis 
and Bordetella parapertussis 
D. Pfrunder', J.M. Hoppel.'. 'Kliiiische Forschiinf, P h r  GmbH, 
Karlsruiie, zUrziversity Children 's Hospitai, 'J%cbiri*qen, Germany 
Objectives: Since no data have been available on the activity of the 
new fluoroyuinolone trovafloxacin against Bordetciia species, this 
study investigated the sutceptibility of B. pertossis and B .  parapertussis 
to trovafloxacin in comparison with moxifloxacin and ciprofloxacin. 
Methods: Minimal inhibitory concentrations (MICs) were deter- 
mined by an agar dilution test procedure using Mueller-Hinton agar 
supplemented with 5%) horse blood. S. aereus ATCC 29213 was used 
as reference strain. 
Results: The table shows MIC ranges, and MICilr and M I C h  
values of the fluoroyuinolones against 34 strains each of B. pertiisxis 
and B. parapertussis. 
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Area - method (cent&) 
Germany - NCCLS (27) 
Austria - NCCLS (14) 
Germany - DIN (44) 
Conclusions: Taking into account the concentrations achievable 
in respiratory secretions, all three agents investigated in this study 
should have good clinical efficacy against both B. pertussis and B. para- 
pertussis. However, clinical trials have not yet been performed. 
% susc % susc I susc % susc 
89.5 82 2 77.8 92 7 
881 805 781 924 
857 100 730 919 
Ip8021 Interpretative criteria for disk susceptibility 
testing of trovafloxacin according to DIN 
58940-a multicenter study for the 
determination of breakpoints for 5-vg disks 
A.F. Schmalreck', D. Bauermeiste?, H.  Grimm3, B. Jansen4, A. 
Rodoff ,  J. WagneP. 'Heinrich Mack, Illertissen, 2Labor Centrum, 
Nordhorn, 'Labor Dr Giirtner, Weingarten, 4Universitiit Main+, Main+, 
5Freie Universitiit, Leipzig, 6Freie Universitiit, Berlin, Germany 
Objectives: To establish interpretative breakpoints for inhibition 
zone diameter (IZD) by agar diffusion testing according to DIN 
58940 using Mueller-Hinton media and 5-pg trovafloxacin disks. 
Methods: 21 16 strains (1535 non-fastidious and 581 fastidious) 
were tested against trovafloxacin by agar difision and microdilution 
test, and against ciprofloxacin by microdilution test. In order to study 
cross-resistance and enable valid regression analysis, a high percent- 
age (29.8%) of ciprofloxacin- resistant strains were included. 
Results: Cross-resistance between trovafloxacin and ciprofloxacin 
was high for Enterobacteriaceae and H .  injuenrae, but not for Gram- 
positive cocci, where trovafloxacin exhibited markedly higher activ- 
ity. IZD breakpoints of 20 mm for susceptible and <16 mm for 
resistant were found by regression analysis based on MIC breakpoints 
of < 1 mg/L and 4 mg/L respectively Differences between fastidious 
and non-fastidious strains were negligible. The regression equation 
was x ' =  -0.26y'*14.63; r=-0.769; 1596 cases were included in the 
analysis after removal of outliers. 
Conclusions: The proposed IZD breakpoints can be used for 
routine susceptibility testing. 
Ip8031 Selection of trovafloxacin disk content and 
species-related calculation of interpretive zone 
breakpoints for disk diffusion susceptibility 
testing 
G. Kronvall', M. Rylander', M. Walder', L. Lind-Brandberg, P. 
Larsson4, E. Tornqvist5, T. Monsen6. 'Department of Laboratory 
Medicine, Division o f  Clinical Microbioloa, Karolinska Institute and 
Hospitals, Stockholm, 'Department of Clinical Bacteriology, MalmO 
University Hospital, Malms, 3Department of Microbiology, University o j  
Gothenbuv, Gothenburg, 4Department of Microbiolofy and Tropical 
Medicine, Sahlgrenska University Hospital East, Gothenbutg, 'Clinical 
Microbiology, Regional Hospital, Orebro, 6Clinical Bacterioloxy, Umed 
University Hospital, Umed, Sweden 
Objectives: Quality control of trovafloxacin disk diffusion testing. 
Methods: Five laboratories in Sweden supplied inhibition zone 
values for more than 7000 clinical isolates tested against ciprofloxacin 
and trovafloxacin 10-gg disks. The reference strains S. aureus ATCC 
29213, E.fecalis ATCC 29212, E. coli ATCC 25922, and I? aerugi- 
nosa ATCC 27853 were also tested. Single strain regression analysis 
(SRA) was performed using the four reference strains and disks 
containing 1, 3, 10, 30 and 100 pg of trovafloxacin. Two ofthe labo- 
ratories used Oxoid IsoSensitest medium and three used Biodisk 
PDM. All adhered to standardization according to the Swedish 
Reference Group. 
Results: Histogram analysis including subtraction histograms of 
the reference strains revealed a difference which correlated with the 
source of medium used. Quality control parameters using SRA 
confirmed this difference. Biodisk PDM medium produced smaller 
zones as compared to the inhibition zones obtained using Oxoid 
IsoSensitest. Rational criteria for the selection of a suitable disk 
content of an antibiotic were applied to trovafloxacin. The 10-pg disk 
selected by NCCLS was found to be optimal. Using common MIC 
limits for the susceptibility categories S, I, and R, the two substrates 
required different interpretive inhibition zone breakpoints. Also, the 
calculated species-related zone diameter breakpoints for E. fecalis and 
P aeruginosa were different from those of S. aureus and E. coli. 
Conclusions: SRA offers a possibility to calibrate the disk dif i -  
sion test and to determine species-related interpretive zone diameter 
breakpoints for the individual laboratory. The methods used also have 
implications for quality control of the disk test. 
JP8041 In vitro activity of trovafloxacin, ciprofloxacin, 
cefotaxime and imipenem determined by disk 
diffusion according to DIN and NCCLS 
guidelines 
A.E Schmalreck', S. Rehm', D. Pfriinde?. 'Heinrich Mack, 
Illertissen, 'Tyizer, Karlsruhe, Germany 
Objectives: Multicenter study in Germany and Austria to determine 
susceptibility patterns and quality control ranges for reference strains 
for the new quinolone trovafloxacin (TVA) versus ciprofloxacin 
(CIP), cefotaxime (CTX) and imipenem (IMI). 
Methods: Susceptibility testing by agar diffusion with 5-pg disks 
according to DIN or with 10-pg disks according to NCCLS guide- 
lines. 
Results: Until the abstract deadline, 16 830 strains were reported 
by the participating laboratories. 8356 isolates (50%) were tested accord- 
ing to DIN and 6357 (38%) according to NCCLS on Mueller- 
Hinton agar. 12% of the isolates were tested on IsoSensitest or DST 
agar. No regional differences in number and type of reported isolates 
or susceptibility pattern were detected. A preliminary analysis (85 out 
of 104 centers) gave the following overall percentage of susceptible 
isolates (including intermediate strains). 
Overall susceptlbllitv I TVA 1 CIP I CTX I IMI 
Conclusions: Although DIN (5-pg disks) and NCCLS (10 pg) 
tests result in similar inhibition zone diameters, interpretation accord- 
ing to NCCLS yields higher susceptibility rates than DIN. 
Trovafloxacin shows higher in vitro activity than ciprofloxacin and 
cefotaxime, and is nearly comparable to imipenem. 
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Antibiotics 
Comparative activity of levofloxacin against F 
aeruginosa and S. maltophilia causing lower 
respiratory tract infection (LRTI) 
I? aeruginosa S. maltophilia 
Range % Susceptibility Range %Susceptibility 
G. Bonfiglio', C. Casconel, C. Azzarelli', E Marchetti', S. Stefani'. 
'Departnient of Microbiology, University of Cutania, Cutania, ZHorrhst 
Mariori Roussell, Italy 
Objectives: The in vitro activity oflevofloxacin (LEVO) against 120 
P aeru'qimsu and 35 S. maltuphilia recent clinical isolates obtained from 
respiratory samples of hospitalized patients with LRTI was evaluated 
in coniparison with ciprofloxacin (CIP), ofloxacin (OFLO), 
ceftazidime (CAZ), intipenem (IMP), piperacillin (PIP) and aimikacin 
(AMK). 
Methods: MIC was determined by the agar dilution method 
using 10' CFU/spot inoculum. NCCLS methodologies and break- 
points were followed. 
Results: The results are shown in the table: 
CAZ 0 5 - 256 1 - 256 
IMP 0.25 - 128 65.8 a- 128 
PIP 0.5 - 2048 80.8 2 - 512 51.4 
AMK 0.5 256 71.7 4 - 256 20.0 
LEVO was the most active antibiotic against both species. LEV0 
and PIP were equally active against P aeruzinosa isolates (80.8% 
susceptibility), but LEV0 was more active against S. maftopliilia 
(82.9% and 51.4% respectively) IME CIP and AMK all showed good 
activity against P aewginosa but very low activity against S. maltophilia. 
Only half of the strains of P aenrginosa and S. maltopkilia were suscep- 
tible to ceftazidime. 
Conclusions: Our finding; suggest that levofloxacin niay be a 
suitable choice when treating LRTI sustained by these microorgaii- 
isms. 
P806 I In vitro and in vivo emergence of resistance 
among S. aureus to ciprofloxacin, levofloxacin, 
moxifloxacin or trovafloxacin 
M. Kouse, K. Piper, R. Patel, W. Wilson, J. Steckelberg. Infctious 
Diseases, Mayo Clinic, Rochester, MA: USA 
Kesistance among S. aureus to quinolone antimicrobials has been 
reported in vitro and in vivo and may negatively influence clinical 
efficacy We compared emergence of resistance. to ciprofloxacin 
(CPO), levofloxacin (LVO), nioxifloxacirl (MXF) or trovafloxacin 
(TVF) among 30 clinical isolates of S. aureus in vitro and in vivo. Each 
isolate was incubated for 24 h in broth containing 1 mg/L of CPO, 
2 mg/L of LVO, 0.5 mg/L of MXF or 2 mg/L of TVE Following 
incubation, each culture was concentrated by centrifugation; the 
bacterial pellet was divided into two aliquots. One aliquot was resus- 
pended in  broth containing antibiotics and returned to the incuba- 
tor. The second aliquot was screened for resistant S. aureus. This was 
repeated daily for 10 days. By clay 10, CPO-resistant subpopulations 
were detected in all 30 isolates of S. aureus. Emergence of resistance 
was not detected after daily incubation with LVO, MXF, or TVE 
Experimental tibia1 osteoniyelitis was established in 112 rats with 8 
isolates of S. aurei4s. Rats were sacrificed after 14 days of C P O  40 
mg/kg SC b.i.d., LVO 25 mg/kg SC, b i d . ,  or MXF 30 mg/kg SC, 
b i d .  S. nureus recovered from at1 bonec were screened for CPO, LVO 
or MXF resistance. Resistant .S. aureus were detected in 23 of 56 
bones from CPO-treated rats, :I of 34 bones from LVO-treated rats, 
and 0 of 22 MXF-treated rats. 
After exposure to CPO, LVO, MXF or TVF in vitro, resistant 
subpopulations of S. au~eiis were detected significantly (P<O.O5) 
more frequently with CPO than LVO, MXF, or TVF. Kesi5tant S. 
auretrs subpopulations were detected more frequently in vivo 
(P<0.05) after 14 days of CPO treatment than after LVO or MXF 
treatment. 
jP8071 Norfloxacin use and resistance in f. coli 
W. Goettsch, W. van Pelt, M.J.W. Sprenger, A.J. de Neeling. 
Infectious Diseuses Epiderniolqyy, Rl VM,  Bilrltoueii, The Nctlierlarcds 
Iwtrodurtiou: Kecerit data froin The Netherlands show that increased 
resistance to norfloxacin in E.  coli isolates from urinary tract infec- 
tions (UTI) is related to fluoroquinolone therapy of urinary tract 
infections. 
Methods: In a continuous surveillance of routine sainples in five 
Dutch laboratories (Goes, Enschede, Ntjmegen, Rotterdam, 
Tilburg), resistance to the antibiotic5 most cominonly prescribed for 
urinary tract infections in The Netherlands, norfloxacin, amoxycillin, 
triniethoprini (or co-trimoxazole) and nitrofurantoin, was studied in 
more than 80 000 E. coli isolates. 
Results: Resistance to norfloxacin steadily increased from 1.3% 
in 1989 to 4.1% in 1997. This increase was mainly due to an increase 
of strains resistant to norfloxacin and at least two of the other three 
antibiotics (from OS% in 1989 to 2.8% in 1997). There was a rela- 
tionship between use of fluoroquinolones (DIlD/case UTI) and 
resistance to nodloxacin in E. roli after stratification for age and 
gender (P< 0.00 1). 
Conclusions: We conclude that resistance to norfloxacin in E. coli 
is still low. However, the increase of strains resistant to norfloxacin 
and at least two of the other three antibiotics may lead to therapy 
problems in the near future. We found a relationshlp between the use 
of fluoroquinolones for therapy of UTI and the percentage of resis- 
tance in E. coli. When the use of fluoroquinolones continues to 
expand in the coming years, we can expect an additional increase in 
resistance to norfloxacin in E. coli. 
I P808] Escherichia coli resistance to quinolones after 
prolonged administration of ciprofloxacin: 
molecular epidemiology and analysis of the 
mechanism of quinolone resistance 
J.P. Horcajada, J. Vila, J. Ruiz, A. Moreno-Martinez, J .A  
Martinez, J. Mensa. Departments of hfectious Discuses a d  
A4icrobioloyy, Hospital Clinic, Barcelona, Spuirt 
Objectives: To investigate the emergence and evolution of qun-  
olone resistance in Escliericliiu coli $trains in fecal specimens from 30 
patients with prostatitis treated with oral ciprofloxacin (750 1119/12 
h) €or 4 weeks. 
Methods: Stool samples were collected before therapy and cvcry 
2 weeks during and after treatment until a quinolone-susceptible E. 
coli strain appeared. The epidenuologic relationship among ?train% was 
determined by REP-PCK and PFGE. The susceptibility to iiahdixic 
acid and ciprofloxacin was performed by Etest and the tnechanisnis 
of quinolone resistance studied by KFLP-PCR Hir!fl of the 
quinolone resistance-determining region (QRDK) of the KyrA gene. 
Results: Four (13%) out of 30 patients showed a qumolone-resis- 
tant E.  culi strain in the first sample. In 10 patients (33%) a quinolonc- 
resistant E. coli strain was detected during treatment. These strains 
were different from those isolated in the first sample except for the 
strains that were already resistant before treatment. During the first 
month after treatment 13 patients (43.3'96) were still excreting 
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quinolone-resistant strains. However, between 20 and 79 days after 
treatment, all the E.  coli strains isolated were quinolone susceptible 
and different from the resistant ones previously detected. All 
quinolone-resistant E. coli showed a t  least a mutation at amino acid 
codon Ser-83 of the gyrA gene. 
Conclusions: Ciprofloxacin administration provokes temporary 
appearance of quinolone-resistant E.  coli strains In fecal flora, but in 
2.5 months the predominant E. coli strains are again susceptible to 
this antiniicrobial agent. These strains are epidemiologically unrelated 
to the quinolone-resistant strains previously isolated and to the 
quinolone-susceptible strains isolated in the first sample. 
Ip8091 Quinolone susceptibility in enterobacteria and 
Pseudomonas aeruginosa in a 2200-bed 
teaching hospital: trends 1992-98 
D. Trystram, E. Cambau, K. Grenet, Y. Pean, V. Jarlier, J. Robert. 
Bacteriology, Pitie-Solpetriere Hospital, Paris, France 
Objectives and methods: Susceptibility (S) to quinolone was eval- 
uated in consecutive, non-repetitive, strains of enterobacteria (EB, n 
=8319) and I? aeruginosa (PA, n ~ 1 4 6 9 )  isolated each year at the 
Pitie-Salpetriere Hospital in August, September and October, in 
1992 (reference period) and from 1995 to 1998. The disk diffusion 
was used with the breakpoints < =8 mg/L for nalidixic acid (nal) and 
< = 1 mg/L for ciprofloxacin (cip) .Results and conclusions: 
Overall, 85% of the strains in EB (89% in E.  coli, 78% in I? mirabilis, 
77% in K. pneumoniae and E. cloacae and 59% in Serratia) were fully 
S to all quinolones, including nal, and no significant time trend was 
observed except in E. cloarae, for which there was a downward trend 
in S to nal from 87% in 1992 to 66% in 1997 (p=O.Ol). Overall, 
among the strains of EB non-S to nal (n= 1273), 53% were still S to 
cip. Between 1992 and 1998, a significant decrease in S to cip was 
observed among EB non-S to nal (15% of the strains), from 66% to 
44%, and among E.  coli non-S to nal (1 1% of the strains), from 94% 
to 43%. The strains of EB non-S to third-generation cephalosporins 
(n=403) were less likely to be S to nal (33%) than the strains S to 
these drugs (n=7916, 87%; P<O.Ol). S to cip in PA remained around 
60% with no significant trend over time. The strains of PA non-S to 
ceftazidime (n=238) or imipenem (n=290) were less likely to be S 
to cip (33% and 33%, respectively) than the strains S to these drugs 
(66% and 67%, respectively, P<O.01). Finally, for the strains of EB 
and PA isolated from urines (n=6523) or from blood cultures 
(n=512), the mean susceptibility to cip remained similar (87% and 
90%. respectively) from 1992 to 1998. 
m1 Increasing fluoroquinolone resistance and 
multiresistance in Salmonelle isolates of 
foreign origin in Finland 
A. Hakane~~ ' .~ ,  A. Siitonen2, P. Kotilainen3, P. Huovinen'. 
'Antimicrobial Researrh Laboratory, National Public Health Institute, 
Erku, 'Nationai Salmonella Referetlce Center, Laboratory o f  Enterir 
Pathogens, National Public Healfk Institute, Helsinki, 'Department o j  
Medicine, Turku University, Turku, Finland 
Objectives: To evaluate the incidence and changes of antimicrobial 
resistance, especially of ciprofloxacin resistance, in Salmonella isolates 
in Finland between 1995 and 1998. 
Methods: During 1995-98 we collected a total of 1011 Salmonella 
isolates, which were considered to be epidemiologically unrelated on 
the basis of routinely collected information. An isolate was designated 
as being of foreign origin if the patient had a confirmed connection 
abroad, e.g. recent travel. All other isolates were designated as being 
of Finnish origin. The Salmonella isolates were collected in four 
phases: each year 1995, 1997 and 1998 starting in January, we consec- 
utively collected 100 Finnish and 100 foreign isolates, and starting in 
September 1996, 200 Finnish and 200 foreign isolates. Serotyping of 
the isolates was performed in the National Salmonella Reference 
Center. MICs were determined by the standard agar plate dilution 
method (NCCLS) for ciprofloxacin and 18 other antimicrobial 
agents. 
Results: During the study period, the number of decreased 
ciprofloxacin-susceptible (DCS, CIP MIC 0.125 mg/L) isolates 
increased from 2.0% to 9.5% (P<0.005) of all isolates. Among the 
isolates of foreign origin the number of DCS isolates increased from 
3.9% to 17%, whereas among isolates of Finnish origin no trend 
could be seen. Multiresistance (resistance to three or more antimi- 
crobial agent groups) was significantly more common among DCS 
isolates (68%) than among all isolates studied (15%) (P<0.001). 
Conclusions: DCS Salmonella isolates emerged in Finland a 
couple of years ago and these isolates are more often multiresistant 
than other isolates. 
Ip8111 French multicenter study on aerobic bacteria 
susceptibility to trovafloxacin and ciprofloxacin 
M.H. Nicolas-Chanoine, J. Goguel. Mitrobiolon, Ambroise-Par4 
Hospital, Boulogne-Billancourt, France 
The aim of this study was to determine (according to the recom- 
mendations of the French Antibiogramme Committee) the suscep- 
tibility of a large set of clinical isolates (n=7255) to trovafloxacin 
(TRO) in comparison with that of ciprofloxacin (CIP). Therefore, 
49 hospital laboratories determined, each by the Mueller-Hinton 
agar diffusion method, the antibiotic susceptibility of 150 consecu- 
tive and non-repetitive aerobic isolates belonging to all species, 
except Haemophilus spp., and obtained from various clinical samples. 
When Streptococcus pneumowiae isolates displayed an oxacillin (5-mg) 
diameter less than 26 mm, the reduced susceptibility to penicillin G 
(PENI) was confirmed by the MIC. All S. pneumoniae isolates, what- 
ever the susceptibility to PENI, were significantly more often suscep- 
tible to TRO (98%) than to CIP (66%). All Staphylococcus aureus 
isolates, and particularly those resistant to methicillin, were signifi- 
cantly more often susceptible to TRO (55%) than to CIP (7%). On 
the contrary, Enterobacteriaceae isolates susceptible (S) or resistant 
(R) to nalidixic acid (NAL) were significantly more susceptible to 
CIP (NAL S, 87%; NAL R 79%) than to TRO (NAL S, 84%; NAL 
R 56%). Gram-positive bacteria isolated from blood (n=486), sinus 
and ear (n= 104), low respiratory tract secretions (LRS: n=308), and 
deep pus (DP: n=971) were significantly more often susceptible to 
TRO than to CIP, whereas Gram-negative bacteria isolated from the 
same samples at an equivalent number were more often susceptible 
to CIP than to TRO, but significantly only from LRS (72% versus 
66%), and DP (82% versus 77%). TRO is a new fluoroquinolone, 
whose spectrum is effectively extended to Gram-positive bacteria. 
Interaction between quinolone, DNA and a 
peptide analog of DNA gyrase 
J. Vila', M. Navia', J. Ruiz', R .  Marchettoj, E. Giralt3. 'Laboratori 
de Microbiologia, Hospital Clinic, 'Department o f  Microbiology, School o f  
Medicine, 'Department of Organic Chemistry, School o f  Chemistry, 
University o f  Barcelona, Barcelona, Spain 
Objectives: The DNA gyrase has been identified as one of the 
protein targets for quinolones. The main objective of this study was 
to investigate the interaction of ciprofloxacin, closed circular DNA 
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and a subunit A DNA gyrase cynthetic peptide as a model to under- 
stand the interaction among these three elements. 
Methods: A peptide mimic of subunit A of DNA gyrase from 
Esrlrerichia colr, which combintd the quinolone resistance-determin- 
ing region and the sequence around the catalytic Tyr-122, was 
synthesized. A6nity chromatography and membrane-filtration tech- 
niques were used to study the interaction of the peptide mimic with 
DNA and ciprofloxacin. 
Results: The peptide mimic hound to ciprofloxacin only when 
DNA and Mg'+ were present (&=1.6XlOF M), which suggested 
that a quaternary complex had been formed. The binding was 
reduced when Ser-83 and Asp87 in the peptide were replaced by 
Leu-83 and ASil-87, a doubk change previously found in the A 
subunit of DNA gyrase in several ciprofloxacin-resistant strains of E.  
roli. 
Conclusions: These results suggect that synthetic peptides 
designed in a similar way to ithat described here could be used as 
mimics of topoisomerases in order to study the structure of the 
enzyme-DNA-quinolone complex. 
Mechanisms of quinolone resistance in 
Stenotrophomonas maltophilia 
J. Vila', J. Ruiz', M. Espasa', M. Navia', 0. del Valle2, M.T 
Jimcnez de Anta'. ' L b o r a t o r i  de hlicrobiolofia, Ho~pital  Clinic, 
LJniversity cf Barceluwa, Barceluna, ' L b o r a t o r i  de hficrobiolo@~, Hospital 
l i l l  d Hebrdn, Spain 
Objectives: To investigate tht: mechanisms of resistance to quino- 
lonec in clinical isolates of S .  rnaltuphili~i and to characterize these 
strains by niolecular epidemiology. 
Methods: Twelve strains of S. maltophilia were epidemiologically 
studied by ERIC-PCR, REP-PCR and macrorestriction analysis. 
The MICs were determined by Etest either in the absence or pres- 
ence of 25 pg/mL of reserpine. Mutations in the quinolone resis- 
tance-determining region of the gyr.4 gene were studied by P C R  and 
DNA sequencing. 
Results: All the studied strziins were epidemiologically unrelated 
in spite of which technique was used. Nine out of 12 strains were 
CIP(S) and NAL(S), 1 strain W.IS CIP(S), NAL(R) and 4 strains were 
CIP(R) and NAL(R). The prttsence of reserpine did not affect the 
MlC of ciprofloxacin; however, it produced a decrease from two- to 
four-fold in the MICs of nalidixic acid. The sequence of the Q R D R  
of the 'yyr.4 gene showed a Gln in position 83 of the A subunit of the 
IINA gyraye in  all the analyzed strains. 
Conclusions: The presence. of Gln at position 83, where usually 
a Ser or Thr iq  found in other microorganisms, seems not affect the 
MIC of ciprofloxacin. Moreover, a likely efflux system influencing 
the resistance of nalidixic acid without affecting ciprofloxacin or 
norfloxacin is found. 
ity of fluoroquinolones (ciprofloxacin, ofloxacin, pefloxacin) related 
to these bacteria was determined. 
Results: The resistance of methicillin-sensitive Stilphylococcits anreus 
(MSSA) and of methicillin-resistant Staphylococcus aimus (MRSA) was 
2% and 34'Vn in the case of ofloxacin, 7% and 36% for pefloxacin, and 
10%1 and 46%) for ciprofloxacin. The resistance of the isolated strains 
of Staphylococcus epidermidis was 50% for ofloxacin and pefloxacin and 
60% for ciprofloxacin. The in vitro activity of fluoroquinolones 
related to MSSA and to MRSA was compared with the activity of 
other antibiotics: gentamicin, erythromycin, rifampicin. 
Conclusions: It appears that important differences exist between 
the resistances of MSSA and MRSA. These data are concordant with 
the resistance of MSSA and of MRSA related to gentamicin, 
rifanipicin, erythromycin, suggesting analogous mechanisms of resis- 
tance. The in vitro activity of ciprofloxacin, ofloxacin and pefloxacin 
related to MSSA, MRSA and Staphylococcus cp ider&f i s  suggests a 
cross-resistance between these fluoroquinolones. 
1-1 Characterization of two sparfloxacin-resistant 
mutants of Staphylococcus aureus obtained in 
vitro: GyrA as the primary sparfloxacin target 
J. Kuiz. J.M. Sierra. M.T. J imhez  de Anta, J. Vila. Department cf 
AIirrobio/o~y, Hvspi td  Clinic, Uniiwsity oj' Barcehino, Barcelona, Spaiw 
Objectives: To characterize the alterations involved in the acquisi- 
tion of spartloxacin resistance in in vitro sparfloxacin-resistant mutants 
of S. aitrcus. 
Methods: Two unrelated strains of S. ai~rens with MICs of 
sparfloxacin of 0.047 and 0.094 pg/niL were chosen. Mutants were 
obtained by growing on plates with increasing concentrations of 
sparfloxacin, until an MIC of sparfloxacin of 2 pg/mL was reached. 
MICs of ciprofloxacin, norfloxacin, and sparfloxacin were deter- 
mined by the Etest method, with and without 15 pg/mL of reser- 
pine. Regions of gyrz4 and 2rL.l containing the Q R D R  were 
amplified and sequenced. 
Results: In both cases GyrA mutated prior to GrIA. In one case 
the inutation present in GyrA (Gly-82 to Cys) does not seem to affect 
the MIC of any of the quinolones analyzed. However, in this strain, 
a posterior mutation present at GrIA (Ser-SO to Phe) was responsi- 
ble for high levels of resistance to nortloxacin and ciprofloxacin, but 
only for moderate levels of resistance to hparfloxacin. With the other 
strain a mutation appeared a t  position 88 of GyrA (Glu to Lys), but 
did not affect the MIC to norfloxacin or ciprofloxacin. However, it 
produced a four-fold increase in the MIC to sparfloxacin. N o  muta- 
tions were present in GrlA. The results also showed that the MlCs 
to ciprofloxacin and nortloxacin were modulated by the activity of 
an efflux pump, which does not affect the Tpadoxacin MIC. 
Conclusions: GyrA may act as a primary target in the case of 
sparfloxacin in S. mreur. Moreover, the increase of S. aureits eiAux 
pumps, likely NorA, does not affect the resistance to sparfloxacin. 
(p8141 The activity of fluoroquinolones related to (p8161 The differential activity of seven 
Staphylococcus aureus and Staphylococcus 
epidermidis Acinetobacter baumannii clinical isolates 
fluoroquinolones against multiresistant 
D. Carstina, A. Slavcovici, N. Sasca. C h i  ?I Infctiotrs Diseases, 
Umvcrsity qf hledicine and Pharmacy, Cluj-Napoca, Romania 
Objectives: To determine the activity of fluoroquinolones related to 
Srapphylococcr~s aurens and to Staphylococcus epidermidis. 
Methods: 120 strains of Staphylococcus aureus and 30 strains of 
Sfaphylorocrus epidermidis were isolated from blood cultures, abscesses, 
sputum and pleural fluid, between 1997 and 1998. The in vitro activ- 
S. Brown, S. Cameron. S.G.B. Amyes. Medical Mrrobiology, 
Uniiwsi fy  qf Edinburgh Medical Srlrool, Edinbiqh, L K  
Acinetobacter baumannii is now universally recognized as an impor- 
tant nosocomial pathogen, with many outbreak5 occurring in inten- 
sive care units in which extensive antibiotic use has \elected for the 
emergence of inultiresistant strains. Many of there strains are now 
resistant to all commonly used antibiotics, including many of the 
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fluoroquinolones and the carbapenems. In some countries, such as 
Argentina, the situation has become so bad that they are already 
beginning to encounter totally resistant clinical strains of Acinetobacter. 
This study investigates the activity of seven fluoroquinolones, includ- 
ing the new quinolones moxifloxacin and trovafloxacin, against 41 
multiresistant A. baumannii clinical isolates from Argentina, Spain, 
Turkey and Hong Kong. Fifty-six per cent of these strains have previ- 
ously been determined as imipenem resistant, and they represent 
some of the most resistant clinical Gram-negative bacteria isolated to 
date. Minimum inhibitory concentrations (MICs) were determined 
by the agar dilution method, with the exception of levofloxacin, 
which was tested by the Stokes method. At standard breakpoints, 
there was significant resistance among these strains to ciprofloxacin 
(68%), norfloxacin (78%) and grepafloxacin (49%). Disk sensitivity 
tests revealed that 56% of the strains were resistant to levofloxacin. 
The least active antibiotic was norfloxacin, with the highest MICso 
and MICw values (256 mg/L for both). Sparfloxaciu, moxifloxacin 
and trovafloxacin were the most active (resistance rates of 14.6%, 
14.6% and 9.7% respectively), with similar and MICro values. 
These newer fluoroquinolones were originally developed to treat 
Gram-positive bacteria but these results demonstrate the possibility 
of a much needed role for these drugs in the treahnent of severe 
Gram-negative infections caused by multiresistant Acinetobacter 
baumannii. 
Laboratory diagnosis: Automation II 
1 P817 1 Comparison of the Fan and Standard 
Bact/Alert blood culture media for the recovery 
of Brucella melitensis 
A. Agulla, M. Rodriguez-Mayo, M. Pereira, M. Fernandez. 
Microbiologia, C.H.A. Marcide Ferrol, Spain 
Objectives: To compare the recovery of Bnrcella melitensis by the Fan 
and Standard BacT/Alert culture media. 
Methods: Ten strains of B. melitensis isolated from patients with 
acute brucellosis and the reference strain B. melitensis ATCC 23456 
were analyzed. A suspension in sterile brucella broth at MacFarland 
0.5 density (lo* CFU/mL) was prepared from an overnight growth 
of each organism, and serial dilutions were performed to obtain lo3, 
lo2 and 10’ CFU/mL inocula. Then 99 Fan bottles and 99 Standard 
bottles were inoculated with 1 mL of these three inocula in tripli- 
cate. Five mL of human blood were added to all media bottles, which 
were vented prior to loading into the BacT/Alert system. Bottles 
were incubated for 21 days or until the instrument signaled that they 
were positive. All negative bottles were terminally subcultured. 
Controls of inocula and blood were performed. 
Results: 55 of 99 bottles were positives from the Fan media with 
the instrument; however, all 44 negative bottles were positives in 
terminal subcultures. 94 of 99 bottles were positives from the 
Standard media in the instrument, 10 of them contaminated. All five 
negative Standard bottles in the instrument were positive in terminal 
subculture. Detection times, media 48 h, did not differ significantly 
between both media. 
Conclusions: The Fan and Standard media were comparable in 
their abilities to recover B. melitensis; however, the BacT/Alert 
System did not detect the microorganism in alI cases. We recommend 
the Standard media when brucellosis is suspected, and perform 
subcultures in these cases. 
I P818 I Value of BACTEC blood culture bottles for 
specimens other than blood 
A.C. Vautrin, A. Carricajo, N. Fonsale, G. Aubert. Bacteriolofy 
Department, Bellevue Hospital, St Etienne, France 
Objectives: To define the microbiological value of BACTEC blood 
culture bottles for specimens other than blood. 
Methods: From July 1997 to August 1998, 501 clinical specimens 
were examined, using both standard bacterial culture and blood 
culture bottles (BACTEC Plus Aerobic/F and BACTEC Lytic/lO 
Aerobic/F, Becton Dickinson). The specimens examined comprised 
aspiration fluids (372). deep abscess isolates (38) and other samples 
(91). The microbiological analysis involved direct microscopic exam- 
ination, as well as standard aerobic and anaerobic bacterial culture. 
The blood culture bottles were placed in the Bactec 9240 incubator. 
Results: 93/501 specimens (18.5%) were positive in culture, 
81/93 being positive both in standard culture and in blood culture 
bottles. 55/501 specimens (10.9%) were positive only in the blood 
culture bottles. The 62 microorganisms recovered from the 55 spec- 
imens were contaminants (16 bacteria) and pathogens (1 1 anaerobic 
bacteria, 3 yeasts, 5 enterobacteria, 9 streptococci, 15 staphylococci, 
1 I? aerqinosa, 1 S. maltophilia, 1 Lactobacillus, 1 Corynebacterium). 
16/30 aerobic bottles were positive with significant pathogens: 10/16 
(62%) were inoculated with specimens which under microscopy 
demonstrated neutrophils and no bacteria, and 13/16 (81%) were 
from patients receiving antibiotics at the time of sampling. 38/44 
anaerobic bottles were positive for pathogens: 25/38 (65%) were 
inoculated with specimens showing neutrophils but no bacteria at 
microscopy and 17/38 (44%) were from patients receiving antibiotics 
at the time of sampling. 
Conclusions: The use of paired aerobic-BACTEC blood bottles 
improves conventional culture sensitivity, particularly for samples 
showing neutrophils but no bacteria at microscopy, as well as for 
samples from patients receiving antibiotics. 
[p8191 Usefulness of MYCO/F Lytic Blood Culture 
System in a clinical laboratory: a preliminary 
report 
J. Esteban, A. Molleja, R. Fernindez-Roblas, M. Jimenez-Arriero, 
E Soriano. Department .f Medical Microbiology, Fundacidn Jimbnez 
Diaz, Madrid, Spain 
Objectives: To evaluate the microbiological and clinical significance 
of results obtained with the use of the MYCO/F lytic system in a 
clinical laboratory. 
Methods: Results of blood cultures (MYCO/F lytic, BBL) sent 
for mycobacterial culture between 1 April 1997 and 15 September 
1998 were reviewed. Positive bottles were inoculated in a Lowenstein- 
Jensen slant, a Middlebrook 7H 11 plate and a Tryptic soy blood agar 
plate. All media were incubated at 3 7 T  and read twice weekly for 
8 weeks. 1.5 mL of liquid were also centrifuged and Ziehl-Neelsen 
and Gram stains were alsp performed from the sediment. 
Results: During the study period, 225 blood cultures were 
processed and 14 of them (6.2%) grew any species of mycobacteria. 
The species isolated were M .  avium (8 samples, 2 patients), and M .  
tuberculosis (6 samples, 4 patients). We also detected true bacteremia 
due to K.  pneumoniae (1 sample), coagulase-negative Staphylococcus 
(CNS) (2 samples from 1 patient) and S.  enteritidis (2 samples from 1 
patient). In 10 bottles (4.4%) the organisms recovered (5 CNS, 3 
Corynebacterium sp. and 2 with both CNS and Corynebacterium sp.) 
were evaluated as ‘contaminants’. 15 bottles were read as positive, but 
no organism could be detected, being considered as false positives. 
The average time for detection ofmycobacteria was 21.73 days (13.7 
